RAPP - CIK 0002012593
The table below shows Rapport Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $20.00M | - | - | $0.00 | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $32.72M | $22.28M | $22.68M | $19.57M | $15.54M | $15.69M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $11.50M |
| - |
| - |
| $7.54M |
| - |
| - |
| Operating income | -$24.21M | -$29.99M | -$29.50M | -$27.11M | -$21.64M | -$20.80M |
| Income tax | - | - | - | - | - | - |
| Net income | -$19.86M | -$26.93M | -$26.73M | -$24.06M | -$17.54M | -$18.12M |
| EPS (diluted) | -$0.42 | -$0.71 | -$0.75 | -$0.68 | -$0.50 | -$1.70 |